Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
- Author:
Salvador VILLÀ
1
;
Carme BALAÑÀ
;
Sílvia COMAS
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antineoplastic Agents, Alkylating; therapeutic use; Brain Neoplasms; genetics; metabolism; therapy; Chemoradiotherapy; DNA Methylation; DNA Modification Methylases; genetics; metabolism; DNA Repair Enzymes; genetics; metabolism; Dacarbazine; analogs & derivatives; therapeutic use; Dose Fractionation; Glioblastoma; genetics; metabolism; therapy; Humans; Radiosurgery; Tumor Suppressor Proteins; genetics; metabolism
- From:Chinese Journal of Cancer 2014;33(1):25-31
- CountryChina
- Language:English
- Abstract: Postoperative external beam radiotherapy was considered the standard adjuvant treatment for patients with glioblastoma multiforme until the advent of using the drug temozolomide (TMZ) in addition to radiotherapy. High-dose volume should be focal, minimizing whole brain irradiation. Modern imaging, using several magnetic resonance sequences, has improved the planning target volume definition. The total dose delivered should be in the range of 60 Gy in fraction sizes of 1.8-2.0 Gy. Currently, TMZ concomitant and adjuvant to radiotherapy has become the standard of care for glioblastoma multiforme patients. Radiotherapy dose-intensification and radiosensitizer approaches have not improved the outcome. In spite of the lack of high quality evidence, stereotactic radiotherapy can be considered for a selected group of patients. For elderly patients, data suggest that the same survival benefit can be achieved with similar morbidity using a shorter course of radiotherapy (hypofractionation). Elderly patients with tumors that exhibit methylation of the O-6-methylguanine-DNA methyltransferase promoter can benefit from TMZ alone.
